Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer
| Autor: | Je-Ho Lee, Byoung-Gie Kim, Chel Hun Choi, Min Kyu Kim, Yoo-Young Lee, Tae-Joong Kim, Duk-Soo Bae, Taejong Song, Hwang-Shin Park, Jeong-Won Lee |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Phases of clinical research Neutropenia Drug Administration Schedule Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Aged Ovarian Neoplasms business.industry Cancer Middle Aged medicine.disease Surgery Regimen chemistry Response Evaluation Criteria in Solid Tumors Camptothecin Female Neoplasm Recurrence Local business Progressive disease Febrile neutropenia |
| Zdroj: | Cancer. 117:2104-2111 |
| ISSN: | 0008-543X |
| Popis: | BACKGROUND: Belotecan (CKD602; Camtobell, Chong Keun Dang Corp., Seoul, Korea) is a recently developed camptothecin derivative with antitumor properties. This phase II study was designed to evaluate the toxicity and efficacy of belotecan combined with carboplatin in patients with recurrent epithelial ovarian cancer (EOC). METHODS: Thirty-eight patients with recurrent EOC were treated with belotecan 0.3 mg/m2/day (days 1-5) and carboplatin AUC 5 (day 5) every 3 weeks for 6 cycles. The primary objective was to determine the response rate as defined by Response Evaluation Criteria in Solid Tumors and CA-125 response. Other end points included toxicities and progression-free survival (PFS). RESULTS: All 38 patients were assessed for toxicity, and 35 patients were assessed for response. The overall response rate was 57.1%; there were 7 complete responses (20.0%), 13 partial responses (37.1%), 6 patients with stable disease (17.1%), and 9 patients with progressive disease (25.7%). Grades 3 and 4 hematologic toxicities included neutropenia (28.8%), thrombocytopenia (19.8%), and anemia (14.4%), and there were 2 episodes of febrile neutropenia. Median PFS was 7 months, with a median follow-up of 12 months. CONCLUSIONS: The newly developed topoisomerase I inhibitor belotecan (CKD-602) combined with carboplatin is a well-tolerated regimen with activity in recurrent EOC. Further testing of this regimen is warranted to further characterize efficacy and indications for use. Cancer 2011. © 2010 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text